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Abstract
Background: Primary spinal cord oligodendroglioma is extremely rare. In an extensive review of this disease, 53
cases were reported. Furthermore, the authors summarize the characteristics of the primary spinal cord
oligodendroglioma; chronological presentation , neurological imaging, treatment and the outcome obtained in the
present case as well as review the literature.
Case Presentation: A 46-year-old male who had progressive neck pain for a year. Magnetic resonance imaging
showed an intramedullary mass from level C2 to T4. A radical resection was performed. Histology revealed
oligodendroglioma. Thereafter, the patient was treated with adjuvant radiotherapy. A year later, tumor developed
recurrence. The patinet died in 3 years and 6 months.
Conclusions: The available data of this disease was limited. Base on 11 published papers and the present case,
surgical resection is the treatment of choice although recurrence of the tumor tends to occur after partial resection
with or without radiotherapy. From the literature, the management of the recurrent disease is still surgery.
Moreover, Temozolomide may be an advantage in recurrent situations.
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Background
Oligodendroglioma originates from oligodendrocyte,
which is found in either the brain or spinal cord [1].
This tumor is commonly found in the cerebral hemi-
sphere while both primary and drop metastasis spinal
oligodendroglioma are an unusual presentation of a
disease [2, 3]. The lack of clinical information means
there is no standard treatment in current practice.
The authors report a case and review modality of
treatment and prognosis from the literature.
Case presentation
A 46-year-old male was presented with progressive neck
pain for a year. The symptoms began without any ante-
cedent event. The symptoms were worse for 5 months.
One month before admission, the patient developed left
arm weakness and numbness in both arms. However, he
had no urinary incontinence. Physical examination dem-
onstrated grade 4/5 muscle weakness in the left arm.
Other extremities revealed grade 5/5 of motor strength.
Pinpricked sensation was suspended deficits at C5-T1
levels. Biceps, triceps and brachioradialis, knee and
Achilles reflexes were 2+. Further, Hoffman reflexes
were absent.
Magnetic resonance imaging (MRI) of the spine showed
an intramedullary mass 12.5 cm long from C2 to T4 level.
The mass was isointense on T1-weighted images, hyperin-
tense on T2-weighted images. Gadolinium-enhanced MRI
demonstrated a heterogenous intramedullary mass. Add-
itionally, syringomyelia was observed above the tumor on
T2-weighted images (Fig. 1).
The patient was operated on under general anesthesia.
Laminectomies were performed. A dural incision was
made. The arachnoid was opened and secured with
dural edges by 4/0 prolene sutures. Expansion of the
spinal cord was observed. A dorsal midline myelotomy
approach was performed. A redness tumor was identi-
fied. The characteristics of the tumor were gelatinous,
and infiltrative. Tumor dissection was done with diffi-
cultly and tumor bleeding was observed during the
dissection (Fig. 2, Additional file 1). The tumor was par-
tially removed using microsurgical techniques. After sur-
gery, the neurological deficits were stable. Postoperative
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MRI revealed some amount of residual tumor remained
in place and an improvement of syringomyelia.
Histologically, the tumor consisted of a fried egg
appearance neoplastic cell, with a uniformly round nu-
clei and clear cytoplasm. Immunochemistry showed
positive for glial fibrillary acidic protein (GFAP). On the
basis of these findings, the tumor was diagnosed oligo-
dendroglioma (Fig. 3).
After diagnosis, the patient was sent for an MRI of
the brain. Imaging demonstrated no intracranial tumor
(Fig. 4). Two weeks later, the patient received
postoperative radiotherapy (45 Gy/25 fractions). Twelve
months after resection, the patient rapidly developed
urinary incontinence and paraplegia. On neurological
examination, his muscle power was grade 0/5 in both
upper and lower limbs. Furthermore, loose sphincter
tone and hyperreflexia of all extremities were detected.
MRI of the spine revealed recurrence of tumor with ex-
tension to the previous surgical wound (Fig. 5). A sec-
ondary operation was considered, but the patient and
his relatives denied surgery. Unfortunately, he died in
3 years and 6 months after surgery.
Fig. 1 An MRI of the cervicothoracic spinal cord. Gadolinium-enhanced sagittal T1-weighted image (a) showed an enhanced intramedullary
tumor from C2 to T4 level. Sagittal T2-weighted image (b) showed syringomyelia above tumor
Fig. 2 A photograph of an intraoperative finding. Posterior midline myelotomy (a) was done on expanding the spinal cord. An intramedullary
tumor at the tip of suction (b) was gelatinous, reddish in color and difficult to discriminate from spinal cord
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Fig. 4 An MRI of the brain. Coronal T2-weighted (a) and axial T1-weighted image (b) showed no intracranial tumor
Fig. 3 Photomicrographs of the intramedullary specimen. Hematoxylin and eosin stain with original magnification (a) showed a sheet of a highly
cellular tumor. At 400 times magnification (b), tumor cells consisted of hyperchromatic nuclei and clear cytoplasm as a fried egg appearance.
Glial fibrillary acidic protein stain (c) with 100 times magnification showed marked positive immunoreactivity
Fig. 5 Gadolinium-enhanced sagittal T1-weighted image of the spine at 3 months (a) and 12 months (b) postoperatively showed a small residual
tumor located the C3-5 level and tumor recurrence surrounding previous surgical field respectively
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Discussion
Oligodendrocytes are the myelination cells of the
brain and spinal cord. In the spinal cord, most oligo-
dendrocyte derived from oligodendrocyte precursor
cells at the ventral ventricular zone, which migrate
through the spinal cord and differentiate into oligo-
dendrocytes [1]. Oligodendrogliomas are one of the
primary brain tumors usually occurring in the cerebral
hemispheres while these tumors of the spinal cord are
rare. To the authors’ knowledge, only 53 cases have
been reported in literature [4–19].
In 1980, Fortuna et al. reported the landmark paper
that collected all the previously reported 37 patients
in table [4]. Guidetti et al. reported one case in a
large clinical series of 129 intramedullary tumors [5].
Alvisi et al. reported two other cases in 1984 [6].
Additionally, Pagni et al. reported a “holocord” type
of primary spinal oligodendroglioma that was located
from craniocervical junction to the conus in 1991 [7].
Wang et al. reported another pediatric case in 1993
[8]. Later in 1994, Cristante et al. reported another
case [9]. Constantini et al. reported one case a few
years later [10]. Nam et al. [11] presented intramedul-
lary anaplastic oligodendroglioma in a child in 1998.
Therefore, Ushida et al. reported the widespread type
of tumor that extended more than ten vertebral levels
in 1998 [12]. Gilmer-Hill et al. reported a pediatric
case with gliomatosis in 2000 [13]. Miller et al. and
Aman et al. [14, 15] Later, found two patients with
this type of tumor. Fountas et al. reported a case of
anaplastic oligodendroglioma that was intradural
extramedullary in 2005 [16]. The total numbers of
spinal oligodendroglioma cases were 50 in 2005. A
year later, Gürkanlar et al. published another case of
intradural extramedullary tumor at L1-2 level [17].
Interestingly, Ramirez et al. reported a case of pri-
mary spinal anaplastic oligodendroglioma that devel-
oped a secondary brain metastasis 2 years after spinal
surgery [18]. In 2011, Wang et al. reported a case of
spinal anaplastic oligodendroglioma associated with
1p deletion [19]. In summary, the number of cases
was 53 in 2011. However, the available data of pa-
tients was limited. Base on 11 published papers and
the present case, the authors reviewed the treatment
and prognosis of cases in Table 1.
In literature, Ushida et al. reviewed the characteristics
of patients with this tumor. The mean age was 28.4 years,
no significant difference in sex [12]. Spinal pain that
included back pain, buttock pain and sciatica was the
most common first symptom for 69.3 % whereas the
most common symptom on physical examination was a
sensorimotor deficit [4]. According to the location of
spinal cord, these tumors have been found frequently in
the thoracic (30 %), cervical (25 %) and lumbar (5 %)
area respectively [16]. Furthermore, this disease fre-
quently presented with an intramedullary lesion in the
spinal canal. Intradural extramedullary was an unusual
presentation [16, 17]. Common spinal features on MRI’s
were isointense in T1-weighted images and hyperintense
in T2-weighted images and heterogenous enhancement
in Gadolinium-enhanced sagittal T1-weighted images [7,
12, 16–19]. Uncommon findings might be found as an
adjacent cystic component [11–13], microhemorrhage
[4, 16, 19]. Diagnosis of this disease are difficult to dis-
tinguish from other gliomas by MRI because these find-
ings can find in spinal astrocytoma and ependymoma
[20]. However, microcalcification is important finding,
which mentioned oligodendroglioma similar to intracra-
nial oligodendroglioma [11, 16]. Regarding to histology,
Most of the tumors are oligodendroglioma WHO
grade 2. Wang et al. reviewed 8 cases, which were
anaplastic oligodendroglioma in the literature and
added a case [19].
From Table 1, surgical resection is the treatment of
choice. Unfortunately, gross total resection is so difficult
because almost all tumors are the intramedullary type.
In the literature, gross total resection was achieved in
only 16.6 % (2/12) of the cases. Moreover, tumor recur-
rence was observed almost 42 % (5/12) within 8 months
to 2 years. Second operation was mentioned in recurrent
situation with postoperative adjuvant therapy. The bene-
fit of radiation therapy is still controversial. Nam et al.
reported outcome of anaplastic oligodendroglioma,
which was treated with partial tumor resection and post-
operative radiation. The patient has no progression of
residual tumor after 50 months follow up [8]. However,
Ramirez et al. and Wang et al. were reported the pa-
tients whom are treated with partial tumor resection
and postoperative radiation too [18, 19]. Unfortunately,
both patients have progressive disease.
The adjuvant chemotherapy has been mentioned to
treat recurrent scenario [13, 19]. Temozolomide (TMZ)
that is a novel alkylating and methylating agent has been
reported the benefits in oligodendroglioma [21]. Adju-
vant TMZ treatment has recently reported in relapse
conditions. The patient who was operated in the second
time received postoperative TMZ to treat the residual
tumor. Complete resolution of the residual tumor within
six months of TMZ chemotherapy was observed on
MRI of the spine [19].
Conclusions
Primary spinal cord oligodendrogliomas are extremely
rare tumors. In spite of limited data of treatment, surgi-
cal resection is the treatment of choice although recur-
rence of the tumor tends to occur after partial resection
with or without radiotherapy. From the literature, the
management of the recurrent disease is still surgery.
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Symptoms Location Histology Treatment Outcome
Fortuna
et al. [4]
32/F LBP, paraparesis T10-T11 Oligo Bx NA
Guidetti
et al. [5]




sensation involved at neck
and shoulder and tetraparesis
IM at C5-T2 Oligo PR 2 years, improvement
Wang
et al. [8]
3/M Scoliosis Thoracolumbar AO PR and RT NA
Nam
et al. [11]





AO PR and RT 50 months, no progression of tumor
Ushida
et al. [12]

















spinal Bx (Oligodendroglioma) and CMT
-10 months after CMT, recurrence at temporal lobe-4th PR and RT-
(AO)-4 months after RT, recurrence at occipital lobe-5th PR and
CMT (AO)-7 months after surgery, stable disease
Fountas
et al. [16]
16/F Neurogenic bladder, left ankle
weakness and sensory deficit
of S1 nerve root on the left.
IDEM with extension
at T11-L2
AO TR 28 months, no recurrence of tumor
Gürkanlar
et al. [17]
56/M Bilateral leg pain IDEM at L1-L2 with








AO PR and RT 2 years, brain metastasis
Wang
et al. [19]





AO 1st PR and RT -8 months, tumor recurrence-2nd PR and TMZ-1 year after TMZ,
no recurrence of tumor
Present
case
46/M Neck pain, left arm weakness,




Oligo PR and RT -1 year, tumor recurrence
Abbreviation: AO Anaplastic oligodendrogliomma, Bx Biopsy, C Cervical, CMT Chemotherapy, F Female, LBP Low back pain, IDEM Intradural extramedullary, IM Intramedullary, M Male, NA Not available, Oligo











Moreover, TMZ may be an advantage in recurrent
situations.
Consent
Written, informed consent was obtained from the pa-
tient for publication of this case report and accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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Additional file 1: A video of an intraoperative finding. (MP4 14804 kb)
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